Haleos Labs Limited has announced a strategic development collaboration with HRV Global Life Sciences Private Limited ("HRV Global") to expedite the development and GMP manufacturing of orphan drug and niche therapeutic Active Pharmaceutical Ingredients (APIs). This partnership is designed to target regulated and semi-regulated markets.

The collaboration leverages Haleos Labs' USFDA-GMP aligned systems and API manufacturing expertise, while HRV Global will contribute its capabilities in global market access and regulatory execution. The objective of this venture is to support Haleos Labs' strategic aim of expanding into high-value APIs for underserved therapeutic areas. It is also expected to bolster the company's presence in key markets such as the US, EU, Latin America, MENA, and APAC through coordinated development and regulatory strategies.

Haleos Labs Limited, formerly known as SMS Lifesciences India Limited, will provide further updates on material developments regarding this collaboration as required by SEBI regulations.